Genenta Science (NASDAQ:GNTA) announced that it has amended its development and master services agreement with contract development and manufacturing organization (CDMO) AGC Biologics to bolster production capabilities and potentially improve efficiency and reliability of its manufacturing processes.
The company stated that the amendment includes the introduction of an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s cell therapy products and ensuring compliance with cGMP standards.
Genenta’s metastatic renal cell cancer (mRCC) Phase 1/2a trial began late in 2024, with the company expecting to treat six patients by the end of the first half of 2025, while continuing progress in its glioblastoma multimforme (GBM) study. Altogether, Genenta projects the production of 27 autologous drug products in 2025.
In a statement, Pierluigi Paracchi, CEO and co-founder of Genenta, said, “Our strengthened partnership with AGC Biologics represents our unwavering commitment to patients participating in our GBM and mRCC trials. This enhanced capacity ensures that we can treat a larger number of patients and further validate our therapeutic approach, bringing us closer to our vision of transforming cancer treatment through cell-based therapies.”
